Jaguar Health Inc (NASDAQ:JAGX) Stock Continues to Trend Lower: Down 14% This Week
Shares of Jaguar Health Inc (NASDAQ:JAGX) have been under pressure over the past few trading sessions.
Market Stats
On Wednesday, JAGX stock fell 6.90% at $1.62 with more than 2.55 million shares, compared to its average volume of 1.92 million shares. The stock has moved within a range of $1.6100 – 1.7800 after opening trading at $1.70.
Jaguar Health’s Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
Commercial stage pharmaceuticals company focusing on developing novel, plant-basedprescription medicines for GI distress, Jaguar Health Inc (NASDAQ:JAGX), announced appointment of veteran of Europe’s pharmaceutical industry, Massimo Mineo as Napo EU’s general manager.
Lisa Conte, Jaguar’s president and CEO and Napo EU board member expressed delight on having Massimo on board for the key leadership role at Napo EU in Milan. Conte added that Massimo is a distinguished leader and senior manager in European pharmaceutical arena having significant experience in orphan-drugs. This would support the company’s focus on pursuing the conditional marketing authorization pathway from the European Medicines Agency.
Mineo will be responsible for planning, strategy as well as implementation of the company’s operational and product development activities in Europe.
His previous stints include Global Director for the Rare Diseases Business Unit at Recordati Rare Diseases, where he joined in 2015 encompassing Europe and Middle East Commercial Operations.
Mineo has a master’s degree in Business Administration and has over two decades of experience in the pharmaceutical industry, particularly in Commercial as well as Finance.
He has also served in Sigma-Tau, in various roles of responsibility in Finance and Administration in the group’s holding company. Mineo expressed excitement on the opportunity to lead the Napo EU team and looks forward on goal of expanding European access to crofelemer to people in need.
Traders Corner
JAGX stock is trading below the 20-Day and 50-Day Moving averages of $1.96 and $2.12 respectively. Moreover, the stock is trading below the 200-Day moving average of $4.34. The stock is down 20% in the past month.